AlphAIAlphAI — Financial news for AI agents
investing.comOCT 202 min read$COR

Cencora stock price target raised to $380 by Argus on growth outlook

Argus raised its price target on Cencora Inc. (NYSE:COR) to $380, citing sustainable earnings growth and an attractive valuation. The company reported Q3 2026 adjusted earnings of $4.48 per share on $84.8 billion revenue, exceeding expectations. Cencora increased its full-year profit outlook despite some Walgreens volume moving away. RBC Capital maintained a Sector Perform rating with a $330 price target, noting growth in specialty pharma but lacking high-margin businesses.

Original reporting
investing.com
Published Oct 20, 2026, 12:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 12:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$COR
Bullish
high confidence
Mentioned
$COR
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CORBullishMed
01

Why it matters

The price target increase reflects confidence in earnings growth and dividend sustainability.

02

Market read

Analyst upgrade could trigger buying pressure in COR and related distributors.

03

What to watch

FTC scrutiny of industry M&A could constrain future growth.

Relevance 7/10Novelty 7/10Timing: today

Background

Cencora, formerly AmerisourceBergen, is a leading U.S. drug distributor; analyst coverage often moves the stock.

Company-level read

Ticker impact

$CORBullishHigh confidence
Context

Argus raised its price target on Cencora Inc. (NYSE:COR) to $380 and reaffirmed full-year guidance after reporting Q3 earnings.

Expected impact

likely upward pressure as investors price in the higher target and solid earnings.

Evidence & confidence

The new $380 target represents a significant increase and follows strong Q3 results, prompting buying interest.

Market effects

Sector

Positive outlook may lift other pharmaceutical distributors.

Regional

U.S. healthcare sector could see modest gains.

Global

Limited to U.S. pharma distribution niche.

Counterpoint

What could challenge this read

Target raise may be premature if Walgreens volume shift materializes.

Key entities

  • Company
    Cencora Inc.

    U.S. pharmaceutical distributor.

  • Analyst
    Argus Research

    Equity research firm that raised the target.

Read at source← All news

StoryArgus raises Cencora price target to $380

Related articles

OCT 21
$CORHighAI 9/10

Cencora, Inc. (COR): Results of Operations and Financial Condition

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CENCORA TO ACQUIRE AMERICAN ONCOLOGY NETWORK TO STRENGTHEN SUPPORT OF COMMUNITY ONCOLOGY Builds on Cencora’s MSO platform by adding complementary capabilities and expanding presence across twelve additional states CONSHOHOCKEN, PA & FORT MYERS, Fla., October 21, 2026

SEC EDGAR 8-K2 min
OCT 21
$CORHighAI 9/10

Cencora to acquire American Oncology Network for $2.4 billion

Cencora Inc. (NYSE:COR) will acquire American Oncology Network Inc. (OTCQX:AONC) for $2.4 billion, including $2.3 billion at closing and up to $100 million in contingent value rights. The deal will expand Cencora's oncology services platform. Cencora expects the acquisition to be accretive to earnings per share by the second year post-closing and updated its 2026 EPS guidance to at least $17.90. The transaction is subject to regulatory approvals and AON stockholder approvals.

investing.com2 min
OCT 21
$CORHighAI 9/10

Cencora, Inc. (COR) to Acquire American Oncology Network for $2.4B EV

Cencora (COR) agreed to acquire American Oncology Network for $2.4B EV, with $2.3B paid at closing and up to $100M in contingent value rights. Cencora expects to pay about $1.7B for 75% ownership if 25% equity is rolled. The deal is expected to be EPS accretive in year two, subject to approvals. According to Cencora, the acquisition aligns with its strategy to expand in oncology services.

tradingview.com1 min
OCT 21
HighAI 8/10

Cancer-practice support would expand to 12 more states under Cencora's planned acquisition

Cencora plans to acquire American Oncology Network (AON), expanding its oncology services to 12 more states. The deal aims to enhance care access and support independent practices. Cencora expects the acquisition to be accretive to its adjusted diluted EPS in the second year post-closing. The transaction is subject to regulatory approvals and AON stockholder approvals.

stocktitan.net2 min
OCT 20
$CORMed

COR Maintained by Argus Research -- Price Target Raised to $380

Argus Research maintained a 'Buy' rating on Cencora (COR) and raised its price target to $380 from $340. The company's GF Value™ suggests it is 11.3% overvalued, with a GF Score™ of 70/100. Insider activity shows significant selling, totaling $4.69 million over the last three months. Cencora operates in pharmaceutical distribution with a market cap of $64.88 billion.

gurufocus.com2 min
SEP 19
$CORHighAI 8/10

Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?

Cencora (COR) reported Q3 revenue of $84.8B (+5.1%) and adjusted EPS of $4.48 (+12.0%). The company raised its full-year adjusted EPS outlook to $17.75-$17.95 and repurchased $1B in stock. Adjusted operating income rose 17.0%, driven by gross profit growth and the OneOncology acquisition. However, operating expenses increased 26.8%, and financing costs rose due to new debt. Lower-margin GLP-1 drugs and lost customers impacted revenue growth.

yahoo.com2 min